Effect of chemotherapeutic drugs on telomere length and telomerase activity by Bolzán, Alejandro Daniel
Telomere and Telomerase 2016; 3: e1488. doi: 10.14800/tt.1488; © 2016 by Alejandro D. Bolzán 
http://www.smartscitech.com/index.php/tt 
 
Page 1 of 11 
 
 
 
 
Effect of chemotherapeutic drugs on telomere length and 
telomerase activity 
 
Alejandro D. Bolzán 
 
Laboratory of Cytogenetics and Mutagenesis, Multidisciplinary Institute of Cell Biology (IMBICE, CICPBA-UNLP-CONICET La 
Plata), P.O. Box 403, La Plata, 1900, Argentina  
 
Correspondence: Alejandro D. Bolzán 
E-mail: abolzan@imbice.gov.ar or adbolzan64@gmail.com 
Received: December 05, 2016 
Published online: January 09, 2017 
 
 
Telomeres are specialized nucleoproteic complexes localized at the ends of eukaryotic chromosomes, that 
maintain their stability and integrity. They protect chromosome ends from fusion and from being recognized as 
sites of DNA damage, i.e., they distinguish natural DNA ends from DNA ends resulting from breakage events. In 
mammalian cells, telomeres consist of tandem arrays of the hexanucleotide TTAGGG, oriented 5′ to 3′ towards 
the end of the chromosomes and associated proteins (the so-called “shelterin” complex), and a large non-coding 
RNA (named TERRA) which forms an integral component of telomeric heterochromatin. Telomere length is 
maintained by a dynamic process of telomere shortening and lengthening. Shortening can occur due to 
nucleolytic degradation and incomplete DNA replication due to the inability of lagging strand synthesis to 
completely replicate chromosomal ends (i.e., the “end replication problem”), whereas lengthening is primarily 
accomplished by the action of the enzyme telomerase and occasionally by the so-called Alternative Lengthening 
of Telomeres (“ALT”) mechanism, which involves homologous recombination. The maintenance of telomere 
function is crucial for genomic stability and cell viability. Cells respond to dysfunctional telomeres by 
undergoing senescence, cell death, or genomic instability. Since telomeres play a fundamental role in 
maintaining chromosomal/genomic stability and telomerase activity and telomere lengthening play a key role in 
cancer development and progression, a proper knowledge of the effects of chemotherapeutic drugs on telomere 
length and telomerase activity in normal as well as tumor cells is of great importance to understand the genomic 
instability associated with chemotherapy regimens. Therefore, in this review we will summarize our current 
knowledge concerning the main data available about the effects of chemotherapeutic drugs on telomere length 
and telomerase activity in mammalian cells. 
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Introduction 
Telomeres are specialized nucleoproteic complexes 
localized at the ends of eukaryotic chromosomes, that 
maintain their stability and integrity [1-3]. They protect 
chromosome ends from fusion and from being recognized as 
sites of DNA damage, i.e., they distinguish natural DNA 
from DNA ends resulting from breakage events [1-3]. 
REVIEW 
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In all vertebrates, telomeres are composed of tandem 
arrays of the hexanucleotide TTAGGG, oriented 5′ → 3′ 
towards the end of the chromosome, ending in a 3′ 
single-stranded overhang ranging in length from ~50 to 400 
nt [4-6], bound by a specialized multiprotein complex known 
as “shelterin” [7], constituted by 6 proteins (POT1, TPP1. 
TIN2, TRF1, TRF2 and RAP1). Shelterin proteins are 
charged with protecting chromosome ends from activating a 
DNA damage response, inhibiting inappropriate repair 
mechanisms, and maintaining telomeric length and structure 
[7]. Telomeres also comprise (UUAGGG)n-containing RNA 
molecules (TERRA), a long non-coding RNA that is 
transcribed from telomeric DNA by RNA polymerase II [8-9]. 
TERRA has been implicated in several processes related to 
telomere function, including telomerase regulation, telomere 
chromatin organization and gene expression [8-10].  
Telomere length is maintained by a dynamic process of 
telomere shortening and lengthening. The telomeres are 
progressively lost with each round of cell division, losing 
approximately 20-300 bp of repeat sequences every cell 
division mainly due to the “end replication problem” (i.e., the 
inability of DNA polymerase to replicate DNA to the ends of 
linear chromosomes) [3]. This is the main mechanism for the 
loss of telomeric repeats and is termed replicative erosion or 
replicative shortening, which leads to replicative senescence 
of cells. Telomere erosion refers to a dysfunctional telomere 
(i.e., a telomere which has lost their end-capping function) 
which became critically short, so it cannot function properly. 
There is another kind of telomere shortening, termed 
“stress-dependent shortening”, which is produced by 
stress-inducing factors like radiation, oncogenes, oxidative 
damage within telomeric DNA, and chromosome 
end-specific exonuclease activity [11-14]. Telomere shortening 
can promote genome instability, which may lead to cancer [3, 
15]. 
To avoid telomere shortening, some cells activate 
telomerase, a reverse transcriptase (i.e., a RNA dependent 
polymerase) that elongates chromosomes by adding 
TTAGGG sequences to the end of chromosomes. Telomerase 
is a ribonucleoprotein composed of dyskerin, the catalytic 
subunit termed TERT, and the RNA subunit named TERC, 
which serve as template to synthesize telomere DNA [3, 10, 16]. 
Although inactive in most somatic cells -with the exception of 
a transient S phase activity thought to maintain the 
single-stranded overhang- telomerase is active in immortal 
cell lines, germline cells, stem cells, activated lymphocytes, 
and most of the tumor cells analyzed so far [10, 16]. Loss of 
telomerase enzymatic function leads to progressive telomere 
shortening over time, eventually resulting in the 
disappearance of detectable telomeric DNA and the formation 
of end-to-end chromosome fusions, followed by growth arrest 
or cell death [10, 16, 17]. In addition to telomere length 
maintenance, telomerase is also involved in other cellular 
processes not directly related to telomere function, including 
gene expression regulation, cell proliferation, apoptosis and 
cell signaling, adhesion and migration [10]. All these activities 
of telomerase are thought to contribute significantly to the 
process of carcinogenesis. In fact, telomerase upregulation or 
reactivation is a critical feature in over 90 % of cancers [10]. 
Because of this, telomerase has been a prime target for the 
development of effective therapeutics against cancer [10]. 
Telomere elongation can also occur in the absence of 
telomerase through the so-called ALT (for ‘alternative 
lengthening of telomeres’) mechanism, which involves 
homologous recombination between telomeres and has been 
described in several tumor cells and immortalized cell lines 
[17, 18]. The ALT mechanism is employed by 10-15 % of 
tumors [17, 18].  
Many drugs used in conventional chemotherapy for the 
treatment of cancer induce genome instability and affect 
telomere function. Thus, several studies have shown that 
cancer patients treated with chemotherapeutic agents and 
radiation have shorter telomere in their blood cells, even after 
the end of the treatments [19-24]. Because telomere plays a 
critical role in regulating cellular life-span, aging and 
genomic stability, telomere shortening or erosion likely 
contributes to late side-effects occurring in long-term 
survivors of cancer patients. It has been suggested that 
repeated exposure to chemotherapy and radiotherapy may 
cause telomere dysfunction through which organ impairment 
and genomic instability take place [25]. Thus, telomere 
dysfunction will eventually contribute to undesirable 
side-effects in long-term survivors of cancer patients, such as 
the development of secondary tumors. Since telomeres play a 
fundamental role in maintaining chromosomal/genomic 
stability and telomerase activity and telomere lengthening 
play a key role in cancer development and progression [10], a 
proper knowledge of the effects of chemotherapeutic drugs 
on telomere length and telomerase activity in normal as well 
as tumor cells is of great importance to understand the 
genomic instability associated with chemotherapy regimens. 
Therefore, in this review, we will summarize our current 
knowledge concerning the main data available about the 
effects of chemotherapeutic drugs on telomere length and 
telomerase activity in mammalian cells.  
Effect of chemotherapeutic drugs on telomere length and 
telomerase activity 
In this section, we will consider the main data available 
concerning the short- and long-term effects of 
chemotherapeutic drugs on telomere length and telomerase 
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Table 1. Effects of chemotherapeutic agents on telomere length and telomerase activity in mammalian cells 
Drug Telomere length Telomerase activity Cell type and references 
Bleomycin ND 
↓↑-- (*) 
 
ND 
ND 
ND 
-- 
-- 
--↑↓ (*) 
 
↑ 
↑ 
-- 
-- 
Chinese hamster cells [32]  
Rat cells (fibroblasts derived from dedifferentiated 
adipose cells) [34, and unpublished data]  
Rat cells (lung fibroblasts) [38]  
Mouse cells (lung epithelial cells) [37]  
Human testicular cancer cells [39] 
Mouse spermatogonial cells [40] 
Streptonigrin ND 
↓↑-- (*) 
-- 
↓ 
Chinese hamster cells [32] 
Rat cells (fibroblasts derived from dedifferentiated 
adipose cells) [35, and unpublished data]  
 
Streptozotocin 
 
ND 
--↑-- (*) 
 
-- 
-- 
 
Chinese hamster cells [33]  
Rat cells (fibroblasts derived from dedifferentiated 
adipose cells) [36]  
Paclitaxel 
 
 
 
Paclitaxel + AZT 
↓ 
↓ 
↓ 
-- 
↓ 
-- 
-- 
↓ 
-- 
ND 
Mouse melanoma cells [42] 
Paclitaxel-requiring mutant CHO cells [43] 
Human pharynx tumor cells [45] 
Human ovarian cancer cells [44] 
Human pharynx tumor cells [46] 
 
Cisplatin 
 
↓ 
ND 
ND 
↓ 
↓ 
↓ 
ND 
ND 
 
ND 
 
ND 
↓ 
↓ 
↓ 
↑ 
↓ 
↓ 
↓ 
 
-- 
 
Hela cells [51] 
Human testicular cancer cells [39]  
Human endometrial cancer cells [48] 
Mouse spermatogonial cells [40] 
Human ovarian cancer cells [44] 
Human hepatoma cells [49] 
Human ovarian cancer cells [50] 
Human head and neck squamous cell carcinoma cell 
lines [52] 
Human haematopoietic cancer cell lines [53] 
 
Doxorubicin 
 
↓ 
-- 
-- 
ND 
↓ 
ND 
ND 
 
↓ 
-- 
↓ 
↓ 
↓ 
↓ 
-- 
 
Human hepatoma cells [49] 
Human ovarian cancer cells [44] 
Human breast tumor cells [54] 
Human breast and stomach cancer cells [55] 
Human normal T-lymphocytes and fibroblasts [25] 
Human ovarian cancer cells [50] 
Human testicular cancer cells [39] 
Etoposide 
 
 
 
 
 
 
 
 
 
Etoposide + Doxorubicin 
Etoposide + bleomycin + cisplatin 
-- 
↓ 
-- 
 
ND 
↓ 
ND 
ND 
ND 
ND 
↓ 
↓ 
-- 
↑ 
ND 
 
-- 
↓ 
↑ 
↑ 
↓ 
-- 
ND 
ND 
Mouse spermatogonial cells [40] 
Human ovarian cancer cells [44] 
Human neuroblastoma and acute lymphoblastic T 
cells [58] 
Human haematopoietic cancer cell lines [53] 
Human normal T-lymphocytes and fibroblasts [25] 
Human leukemic cells [59,60] 
Human pancreatic tumor cell lines [61] 
Human hepatomas and leukemic cell lines [62] 
Human nasopharyngeal carcinoma cells [63] 
Human mesenchymal stem cells [56] 
Rat male germ cells [57] 
 
Azydothimidine (AZT) 
 
 
 
 
 
 
 
AZT + arsenic trioxide 
AZT + 5-FU 
 
↓ 
↓ 
↓ 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
 
↓ 
ND 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
 
Human lymphoid cell lines [65] 
Hela cells [67] 
Human endometrial carcinoma cells [66] 
Mouse mammary carcinoma cells [68] 
Human pharynx cells [45] 
Human parathyroid cancer cells [69] 
Human liver carcinoma cells [70] 
Mouse mammary carcinoma cells [64] 
Human acute promyelocytic leukemia cells [72] 
Human colon cancer cells [71] 
 
5-Azacytidine 
 
5-Aza-2’deoxycytidine ± Trichostatin A 
 
↓ 
-- 
↑ 
 
↓ (expression of TERT) 
ND 
ND 
 
Acute myeloid leukemia cells [75] 
Human glioblastoma cells [76] 
Breast cancer cells [74] 
 
Gemcitabine 
 
↓ 
 
-- 
 
Hela cells [78] 
C-1027 ↓  ND Human colon cancer cells [83] 
ICRF-193 ↓ 
-- 
ND 
ND 
Human osteosarcoma cells [85] 
Human colon carcinoma and cervical cancer cells [85] 
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Melphalan ND 
↑ / ↓ (***) 
-- 
ND 
Human testicular cancer cells [39] 
Mouse bone marrow cells [87] 
5-Fluorouracil (5-FU) 
 
5-FU + Cisplatin 
ND 
 
↑ 
-- 
 
↑ 
Human head and neck squamous cell carcinoma cell 
lines [52] 
Human colorectal carcinoma cells [89] 
Cyclophosphamide  
4OOH-CPA (**) 
↓ 
↓ 
↑ 
↓ 
Human ovarian cancer cells [44] 
Mouse spermatogonial cells [40] 
Mitomycin C ND -- Human haematopoietic cancer cell lines [53] 
Methotrexate ND -- Human testicular cancer cells [39] 
 
↑: increasing effect (telomere elongation); ↓: decreasing effect (telomere shortening or erosion); --: no effect; ND: Not determined. (*) These symbols represent the 
effects of the drug observed at 18 h, 10 days and 15 days after treatment, respectively. (**) 4-hydroperoxycyclophosphamide, a preactivated analog of 
cyclophosphamide. (***) The increasing effect was observed in p53+/- mice, whereas the decreasing effect was observed in wild-type mice.  
activity in mammalian cells. First, we will refer to those 
anticancer drugs whose effects on telomere length and 
telomerase activity have been intensively investigated and 
then we will focus on some anticancer drugs whose effects on 
these parameters are barely know. For a summary of the 
effects of each drug on telomere length and telomerase 
activity, the reader should refer to Table 1. 
Bleomycin, streptonigrin and streptozotocin 
Several years ago, we carried out a series of experiments 
to determine the effects of three antitumoral antibiotics, 
namely, bleomycin, streptonigrin and streptozotocin, on 
mammalian telomeres and telomeric sequences (see [26] for 
review).  
Bleomycin (CAS No. 11056-06-7) is a chemotherapeutic 
drug isolated from Streptomyces verticillus which is 
commonly used to treat testicular cancer, non-Hodgkin 
lymphoma, lung cancer, cervical cancer and cancers of the 
head and neck [27]. This antibiotic is a radiomimetic agent 
that generates free radicals and induces single- and 
double-strand breaks in DNA [27, 28]. Streptonigrin (CAS No. 
3930-19-6) is an aminoquinone antitumor antibiotic isolated 
from cultures of Streptomyces flocculus, which shows 
antitumor activity against a broad range of tumors, including 
breast, lung, head and neck cancer, lymphoma and melanoma 
[29], although its use in chemotherapy is very limited because 
the severe and prolonged bone marrow depression it induces 
[29]. Streptonigrin is also a venom of topoisomerase II, 
inhibiting this enzyme by stabilizing its transesterification 
intermediate (cleavable complex) [29]. Streptozotocin or 
streptozocin (CAS No. 18883-66-4) is an antibiotic isolated 
from Streptomyces achromogenes [30, 31], usually used to 
experimentally induce diabetes mellitus in rats, and 
considered a potential compound for the clinical treatment of 
some malignant diseases, specially advanced pancreatic 
neuroendocrine tumors and colon cancer. Also, 
streptozotocin is a potent alkylating agent that directly 
methylates DNA [30, 31]. 
Despite the abovementioned compounds induced 
chromosomal aberrations involving telomeres and interstitial 
telomeric sequences, none of them altered the activity of 
telomerase in CHO and CHE cells [32, 33], at least in the 
short-term (18 h after treatment). The effect of these drugs on 
telomere length in hamster cells was not determined. More 
recently, we investigated the long-term effect (i.e., up to 15 
days after treatment) of bleomycin, streptonigrin and 
streptozotocin on telomeres of rat cells (the ADIPO-P2 cell 
line, derived from dedifferentiated adipose cells from 
Spragüe-Dawley rats) [34-36]. Bleomycin and streptonigrin had 
a variable effect on telomere length, since they both induced 
telomere shortening at 18 h, telomere elongation at 10 days, 
and had no effect on telomere length at 15 days after 
treatment (Paviolo, unpublished). Nevertheless, these 
compounds had a completely different effect on telomerase 
activity. Bleomycin did not modify the activity of telomerase 
at 18 h after treatment (the same effect previously observed 
in Chinese hamster cells [32]), but produced an increase at 10 
days and a decrease at 15 days after treatment [34]. Thus, 
bleomycin produced a delayed induction of telomerase 
activity in mammalian cells. This finding is in line with that 
of Fridlender et al. [37] who found that this compound induces 
telomerase activity in lung epithelial cells of mice 7 and 14 
days after treatment, and that of Nozaki et al. [38], who found 
elevated levels of telomerase in fibroblasts and tissue extracts 
isolated from bleomycin-injured rat lungs at 7, 14, and 21 
days postreatment, with maximal activity observed in the day 
14 samples. Therefore, we concluded that the observed 
telomere instability induced by bleomycin in rat cells was 
unrelated to telomerase activity [34]. 
On the contrary, streptonigrin induced a persistent 
inhibition of telomerase activity (up to 77%) in 
streptonigrin-treated rat cells in comparison with that of 
untreated (control) rat cells at each time points analyzed (18 
h, 10 days and 15 days after treatment). Therefore, 
telomerase could be involved in the observed telomere 
dysfunction in these cells (through the induction of 
telomere-related chromosomal aberrations [35]), but this 
assumption requires further studies to be confirmed. We 
previously observed in Chinese hamster cells that telomerase 
activity in streptonigrin-treated cells was similar to that of 
untreated cells 18 h after treatment [32]. Thus, the effect of 
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streptonigrin on telomerase activity seems to be dependent 
on the cell type.  
Concerning streptozotocin, we found that it also has a 
variable effect on telomere length in the long-term, since this 
drug had no significant effect at 18 h and 15 days after 
treatment, but induced telomere elongation at 10 days after 
treatment. These effects were not related with telomerase 
activity, which remained unchanged in both treated and 
untreated cells from 18 h to 15 days after treatment [36]. 
Therefore, the persistence of chromosomal aberrations 
related to telomere dysfunction observed in rat cells exposed 
to streptozotocin seems to be unrelated to telomerase activity 
or telomere length. The data registered in telomerase activity 
in the short-term agrees well with the data previously 
obtained in CHO cells, where no variations of the activity 
were observed 18 h posttreatment with streptozotocin [33] in 
comparison to control (unexposed) cells.  
Besides the abovementioned studies, other researchers 
reported additional data on the effect of bleomycin on 
telomere length and telomerase activity. Burger et al. showed 
that bleomycin inhibits telomerase activity in human 
testicular cancer cells [39]. Recently, Liu et al., studied the 
effect of bleomycin and other chemotherapeutic drugs on 
telomeres of a mouse spermatogonial cell line and found that 
this compound did not affect neither telomere length nor 
telomerase activity in these cells [40]. However, bleomycin 
induced telomere DNA damage in these cells, as seen by the 
colocalization of the telomere FISH probe signal with 
immunofluorescent γH2AX foci (a marker of DNA 
double-strand breaks) [40]. No further studies have been made 
concerning the effects of streptonigrin or streptozotocin on 
telomeres so far.  
Paclitaxel 
Paclitaxel or Taxol (CAS No. 33069-62-4) is an anticancer 
drug, isolated from the bark of the Pacific yew Taxus 
brevifolia, that has been shown to be clinically effective 
against ovarian, breast, lung, pancreatic, and other human 
cancers [41].  
It has been shown that paclitaxel and its water-soluble 
forms poly (L-glutamic acid)-paclitaxel, sodium-pentetic 
acid-paclitaxel, and polyethylene glycol-paclitaxel, induced 
extensive telomere erosion (visualized as reduced telomeric 
signal intensity after telomere fluorescent in situ 
hybridization) in a murine metastatic melanoma cell line 
(K1735, clone X-21), but did not affect telomerase activity 
[42]. Similar results were also observed in Tax-18 and 
Tax-2-4, two paclitaxel-requiring mutant CHO cell lines [43]. 
Moreover, paclitaxel did not affect telomere length or 
telomerase activity in human ovarian cancer cells [44]. 
Interestingly, telomere erosion induced by paclitaxel can be 
enhanced by telomerase inhibitors, such as AZT, as 
demonstrated in human pharynx FaDu tumor cells [45, 46]. 
Cisplatin 
Cisplatin (CAS No. 15663-27-1) is a well-known 
platinum-based anticancer drug with alkylating properties, 
which forms DNA adducts and induces apoptosis [47]. This 
compound is used alone or in combination with other 
chemotherapeutic agents for the clinical treatment of several 
types of cancers, including testicular, ovarian and lung 
cancer, among others [47].     
The inhibitory effect of cisplatin on telomerase activity 
was demonstrated in several types of cells, including human 
testicular cancer cells [39], endometrial cancer cells [48], 
hepatoma cells [49], ovarian cancer cells [50] and mouse 
spermatogonial cells [40]. In the study from Liu et al. [40], it 
was also found that cisplatin shortens telomere length, thus 
causing telomere dysfunction. Thus, cisplatin could induce 
long-term telomeric loss in mammalian cells, resulting from 
the inhibition of the enzyme telomerase. Moreover, Ishibashi 
and Lippard [51] by using Analysis of TRF Length (by 
Southern blot) showed that cisplatin induces telomere loss 
(shortening) and degradation in HeLa cells. Cisplatin was 
also found to induce telomere shortening in human hepatoma 
cells [49] and human ovarian cancer cells [44]. However, the 
effect of cisplatin on telomerase activity in human ovarian 
cancer cells is not clear, since one study showed that this 
compound increases telomerase activity [44], whereas another 
study showed that cisplatin inhibited telomerase activity in 
these cells [50]. Moreover, cisplatin was found to inhibit 
telomerase activity in human neck and head squamous cell 
carcinoma cell lines [52]. No effect of cisplatin on telomerase 
activity in human haematopoietic cancer cell lines was 
observed [53]. 
Doxorubicin and etoposide 
Doxorubicin (also called Adriamycin, CAS No. 
23214-92-8) and etoposide (CAS No. 33419-42-0) are both 
topoisomerase II inhibitors with anticancer properties. 
Doxorubicin inhibits telomerase activity in human testicular 
cancer cells [39]. It has been found that doxorubicin inhibits 
telomerase activity and shortens mean telomere length in 
human hepatoma cells [49]. Thus, it has been proposed that 
telomerase inhibition and telomere shortening by 
doxorubicin may contribute to its efficiency in the treatment 
of hepatocellular carcinoma. However, doxorubicin had no 
effect on telomerase or telomere length in human ovarian 
cancer cells [44] or inhibited telomerase activity in these cells 
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(cell line A2780) [50], decreased telomerase activity but had 
no effect on telomere length in breast tumor cells [54], and 
decreased telomerase activity in several human breast and 
stomach cancer cell lines [55]. Thus, the effect of doxorubicin 
on telomeres depends on the cell type.  
A few years ago, it was reported that doxorubicin and 
etoposide induce progressive telomere shortening in human 
mesenchymal stem cells, obtained from bone marrow cells 
from normal adults and grown in the presence of platelet 
lysates [56]. A year later, Li et al. reported that the treatment 
of normal human T lymphocytes and fibroblasts with 
doxorubicin or etoposide led to significant shortening of 
telomeres, down-regulation of telomerase activity, 
diminished expression of TERT and the telomere binding 
proteins TPP1 and POT1 and telomere dysfunction in these 
cells [25]. However, recent data reported by Liu et al. showed 
that etoposide alone does not specifically affects telomeres of 
a mouse spermatogonial cell line and that this drug did not 
induce telomere dysfunction in these cells [40], but in 
combination with bleomycin and cisplatin, etoposide 
produces telomere shortening in rat male germ cells [57]. In 
addition, it was demonstrated that etoposide did not affect 
telomere length in the neuroblastoma cell line SHSY5Y 
(with very short telomeres) or the acute lymphoblastic T cell 
line 1301 (which exhibits extremely long telomeres) [58]. 
Moreover, etoposide has no effect on telomerase activity in 
human haematopoietic cancer cell lines [53] and induces 
telomere shortening and decreases telomerase activity in 
human ovarian cancer cells [44]. Upregulation of telomerase 
activity was observed in the human leukemic cell line HL60 
[59,60], and several pancreatic tumor cell lines after etoposide 
treatment [61]. However, a decrease in telomerase activity was 
observed in hepatocarcinomas and other leukemic cell lines 
[62] and no change in levels of telomerase in nasopharyngeal 
carcinoma cells [63]. Thus, as with doxorubicin, the effect of 
etoposide on telomeres depends on the cell type. 
AZT 
Azidothymidine or zidovudine (CAS No. 9003-98-9), is a 
thymidine analog used in the treatment of AIDS, that also 
exhibits anticancer effects [64]. It has been found that AZT 
inhibits telomerase activity and causes telomere shortening in 
human lymphoid cell lines (the B cell line JY616 and the T 
cell line Jurkat E6-1) [65] and human endometrial carcinoma 
cells [66], produces irreversible telomere shortening in Hela 
cells [67], and inhibits telomerase activity in mouse mammary 
carcinoma cells [68], human pharynx cells [45], human 
parathyroid cancer cells [69], human liver carcinoma cells [70] 
and mouse mammary carcinoma cells [64]. In addition, AZT 
in combination with arsenic trioxide or 5-FU also inhibits 
telomerase activity in human colon cancer cells [71] and acute 
promyelocytic leukemia cells [72]. Thus, AZT clearly inhibits 
telomerase activity in mammalian cells. 
5-AZA 
5-azacytidine (5-AZA, Ladakamycin, CAS No. 320-67-2) 
and its deoxy derivative 5-aza-2’deoxycytidine (Decitabine, 
CAS No. 2353-33-5) are demethylating compounds (inhibit 
DNA methyltransferases) with anticancer properties, usually 
employed against myelodysplastic syndrome and acute 
myeloid leukemia [73]. It has been shown that 
5-aza-2’deoxycytidine, either alone or in combination with 
trichostatin A, induces telomere elongation in breast cancer 
cell lines due to up-regulation of shelterin genes [74]. In 
addition, 5-AZA was found to induce DNA damage at 
telomeres, telomere shortening, diminished TERT expression 
and apoptosis in acute myeloid leukemia cell lines [75]. Thus, it 
was suggested that another mechanism (besides DNA 
demethylation) by which 5-AZA exerts its antitumoral 
activity is telomere dysfunction [75]. On the contrary, 
Choudhury et al., using the glioblastoma cell line SF-767, 
found that 5-AZA caused significant changes in DNA 
methylation of subtelomeric regions of chromosomes but did 
not modify the telomere length in these cells [76]. Thus, further 
studies will be needed to clarify the effect of this compound 
on telomere length and telomerase activity. 
Gemcitabine 
It has been recently reported that the cytidine analog 
gemcitabine (2′,2′-diflurodeoxycytidine) (CAS No. 
95058-81-4), an effective anticancer drug against several 
types of solid tumors, including colorectal, breast, pancreatic, 
renal and lung cancers [77], causes telomere attrition or 
shortening in Hela cells, by increasing the level and stability 
of TRF2 [99]. By increasing TRF2 expression, gemcitabine 
enhances the XPF activity, and because XPF is a nuclease, 
binding of this enzyme to telomeres may lead to 
inappropriate excision of telomeric DNA. The anticancer 
effect of gemcitabine is due to the incorporation of the active 
derivative compound dFdCTP into DNA in proliferating 
cells, leading to inhibition of DNA synthesis and repair. 
Thus, the above findings by Su et al. [78] suggest that the 
promotion of telomere attrition by induction of TRF2 is a 
new mechanism of action of gemcitabine against cancer. This 
effect of gemcitabine seems to be independent of telomerase, 
since this drug had no effect on telomerase activity in Hela 
cells 3 days after treatment. No further studies have been 
made to analyze the effect of gemcitabine on telomere length 
or telomerase activity in mammalian cells. 
C-1027  
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The enediyne antibiotic C-1027 or Lidamycin (CAS No. 
120177-69-7) is a new kind of macromolecular antitumor 
antibiotics, produced by Streptomyces globisporus in soil, 
consisting of a noncovalently bound apoprotein and a labile 
chromophore which is responsible for most of the biological 
activities [79-81]. This drug is a potent anticancer drug with 
radiomimetic properties, which is being currently evaluated 
in Phase II clinical trials [82]. Several years ago, it was 
demonstrated in cultured human colon carcinoma HCT116 
cells exposed to C-1027 that this drug induces telomere 
fusions (i.e., chromosomes joined end to end at their 
telomeres or fused together after complete loss of telomere 
sequences, as seen by telomere FISH) in these cells [83]. 
Therefore, C-1027 induces short-term telomere shortening in 
human cells. No further studies on the effects of C-1027 on 
telomere length or telomerase activity have been performed 
so far. 
ICRF-193  
ICRF-193 ([meso-2, 3-bis (2, 6-dioxopiperazin-4-yl) 
butane], CAS No. 21416-68-2) is a topoisomerase II catalytic 
inhibitor and a well-known anticancer drug for treating acute 
leukemia and lymphosarcoma [84]. It has been demonstrated 
that ICRF-193 causes telomere shortening in ALT cells 
(U2OS and Saos2 human osteosarcoma cell lines) but has no 
effect on telomere length in telomerase-positive cells 
(HCT116 human colon cancer cell line and Hela human 
cervical cancer cell line) [85]. Moreover, ICRF-193 causes 
ALT telomere shortening and inhibits ALT cell proliferation 
in mice [85], which suggests that this drug could be used to 
prevent cell proliferation in cancer cells with an ALT 
mechanism of telomere elongation. No further studies on the 
effects of ICRF-193 on telomere length or telomerase 
activity have been performed so far. 
Melphalan   
Melphalan, L-phenylalanine mustard, L-PAM, Alkeran or 
L-Sarcolysine (CAS No. 148-82-3) is a chemotherapeutic 
drug belonging to the class of nitrogen mustard alkylating 
agents [86]. It has been reported that melphalan has no effect 
on telomerase activity in human testicular cancer cells [39]. 
More recently, by studying the induction and persistence of 
chromosome aberrations in bone marrow and spleen cells of 
p53+/- (and wild type) mice exposed for 4, 13, or 26 weeks 
to 2 mg/kg melphalan, Sgura et al. [87] demonstrated that this 
compound induces telomere shortening in bone marrow cells 
of wild-type mice, while in p53+/- mice the exposure to this 
compound induces telomere elongation. No further studies 
on the effect of melphalan on telomere length or telomerase 
activity have been reported so far. 
 
 
5-FU 
In the case of 5-fluorouracil (CAS No. 51-21-8), a thymine 
analog with anticancer properties commonly used against 
several types of solid tumors, including breast, colorectal, 
pancreatic, skin and cervical carcinoma [88], there is only a few 
reports about its effects on telomere length or telomerase 
activity. It has been shown that 5-FU inhibits telomerase 
activity in human head and neck squamous cell carcinoma cell 
lines [52] and, combined with cisplatin, 5-FU increases 
telomerase activity and causes long-term telomere elongation 
in colorectal carcinoma cells (LoVo and DLD-1 cell lines) [89].  
CPA  
Cyclophosphamide (CAS No. 50-18-0) is an alkylating 
drug with antitumoral properties, clinically used for the 
treatment of lymphoma, brain cancer, leukemia and some 
solid tumors, like cancer of the pancreas, and to induce Type 1 
and 2 diabetes in laboratory animals [90]. Its clinical use is very 
limited due to its toxic effects. There are only a few data 
published concerning the effects of the anticancer drug 
cyclophosphamide on telomere length and telomerase 
activity. Decreased telomerase activity and telomere 
shortening were observed in mouse spermatogonial cells 
treated with the alkylating compound 4OOH-CPA (a 
preactivated analog of CPA) [40]. CPA also induced telomere 
shortening in human ovarian cancer cells, but induced 
telomerase activity in these cells [44]. 
Mitomycin C and methotrexate 
The chemotherapeutic agents mitomycin C (CAS No. 
50-07-7) and methotrexate (formerly amethopterin) (CAS 
No. 59-05-2) -used for the treatment of several types of 
cancer, including gastroinestinal cancers, breast cancer, 
bladder tumors, leukemias, lymphomas and lung cancer-  
were found to inhibit telomerase activity in human 
haematopoietic cancer cells and human testicular cancer 
cells, respectively [39,53]. 
Telomere length and telomerase activity alterations 
induced by chemotherapeutic drugs: Conclusions and 
future prospects. 
The studies reviewed here clearly show that telomere 
length and telomerase activity are differentially affected by 
exposure to chemotherapeutic drugs. However, from these 
studies and the analysis of data from Table 1, we can draw 
some important conclusions: 
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1) For some chemotherapeutic drugs, their effect on 
telomere length and/or telomerase activity is clearly 
established. They induce telomere shortening and/or inhibit 
telomerase activity. Thus, cisplatin clearly causes telomere 
shortening and inhibits telomerase activity, paclitaxel 
induces telomere shortening, and doxorubicin and AZT 
inhibit telomerase activity. Moreover, streptozotocin do not 
alter telomerase activity, even in the long-term. 
2) For other chemotherapeutic drugs (doxorubicin, 
5-AZA, etoposide) contradictory data exist concerning their 
effects on telomere length and/or telomerase activity, so 
further studies are needed to clearly determine these effects. 
3) For several chemotherapeutic drugs (gemcitabine, 
C-1027, ICRF-193, melphalan, 5-FU, CPA, mitomycin C, 
methotrexate) there is only a few data available regarding 
their effects on telomere length and telomerase activity, so 
further studies are needed to clearly establish whether they 
induce telomere shortening or lengthening and whether they 
induce up- or down-regulation of telomerase activity. 
Moreover, in the case of bleomycin, streptonigrin, 
streptozotocin, etoposide and AZT, their effect on telomere 
length is not clearly established yet. 
Despite of the above conclusions, most of the studies 
performed so far have shown that chemotherapeutic drugs 
induce telomere shortening and inhibit telomerase activity. 
Therefore, the data available raise concern about the potential 
risks of a long-term chemotherapy based on the 
abovementioned drugs. Telomere shortening and/or 
telomerase inhibition induced by cytostatic therapy 
theoretically could induce an additional genomic instability 
in neoplastic cells, this effect causing undesirable side 
effects, including secondary malignancies in long-term 
survivors of cancer.  
In summary, for most chemotherapeutic drugs, further 
studies will be needed to fully elucidate their effects on 
telomere length and telomerase activity. Depending on the 
drug, these studies should be aimed at determining whether it 
induces short- and long-term telomere shortening or 
elongation, or down- or up-regulation of telomerase activity. 
Undoubtedly, these studies will contribute to a better 
understanding of the effects of the anticancer drugs on 
mammalian cells, and this information will be of great 
importance to understand the genomic instability associated 
with chemotherapy regimens.  
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